<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">tumors</journal-id><journal-title-group><journal-title xml:lang="ru">Malignant tumours</journal-title><trans-title-group xml:lang="en"><trans-title>Malignant tumours</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2224-5057</issn><issn pub-type="epub">2587-6813</issn><publisher><publisher-name>Rosoncoweb</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18027/2224-5057-2019-9-3s1-32-42</article-id><article-id custom-type="elpub" pub-id-type="custom">tumors-662</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ И АНАЛИТИКА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS AND ANALYSIS</subject></subj-group></article-categories><title-group><article-title>ПРЕИМУЩЕСТВА И НЕДОСТАТКИ ИСПОЛЬЗОВАНИЯ ПРОКАЛЬЦИТОНИНА В КЛИНИКЕ</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Багирова</surname><given-names>Н. С.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><email xlink:type="simple">nbagirova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петухова</surname><given-names>И. Н.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Григорьевская</surname><given-names>З. В.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Терещенко</surname><given-names>И. В.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дмитриева</surname><given-names>Н. В.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>26</day><month>11</month><year>2019</year></pub-date><volume>9</volume><issue>3s1</issue><fpage>32</fpage><lpage>42</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Багирова Н.С., Петухова И.Н., Григорьевская З.В., Терещенко И.В., Дмитриева Н.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Багирова Н.С., Петухова И.Н., Григорьевская З.В., Терещенко И.В., Дмитриева Н.В.</copyright-holder><copyright-holder xml:lang="en">Багирова Н.С., Петухова И.Н., Григорьевская З.В., Терещенко И.В., Дмитриева Н.В.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.malignanttumors.org/jour/article/view/662">https://www.malignanttumors.org/jour/article/view/662</self-uri><abstract><p>В качестве дополнения к другим клиническим и лабораторным параметрам прокальцитонин (ПКТ) предоставляет диагностическую, прогностическую и терагностическую информацию, и прежде всего при сепсисе и инфекциях дыхательных путей. ПКТ информативен при проведении дифференциальной диагностики между лихорадкой инфекционной и неинфекционной природы, бактериальной и вирусной этиологии. При бактериальном сепсисе уровень ПКТ значительно возрастает (обычно более 2 нг / мл), снижаясь при адекватной антибактериальной терапии (АБТ). При вирусных инфекциях значения ПКТ остаются в пределах нормы или незначительно повышаются. У здоровых людей ПКТ не более 0,01 нг / мл, при вирусных инфекциях — редко более 1 нг / мл. ПКТ как прогностический маркер дает возможность корректировать проведение дальнейших диагностических исследований, использовать иные терапевтические стратегии, прежде всего в отношении антимикробной терапии. Введение ПКТ в алгоритм лечения требует серии исследований уровня ПКТ, но не однократного его определения. Эффективное лечение связано с активным снижением уровня ПКТ, тогда как длительно сохраняющийся высокий уровень, как правило, сопровождается летальным исходом. При локализованном очаге инфекции ПКТ рассматривают как прогностический фактор: увеличение ПКТ при повторных исследованиях (интервал 12–24 часа) свидетельствует о генерализации инфекции. Для взрослых пациентов рекомендовано прекратить АБТ, если концентрация ПКТ снизилась на 80 % или более от его пикового значения, или когда она достигла значения 0,5 нг / мл или ниже. После оперативного вмешательства при сепсисе уровень ПКТ ≥ 2,0 нг / мл является наиболее чувствительным и специфичным показателем бактериального сепсиса, когда следует немедленно начать АБТ после тщательного клинического обследования, нужен контроль уровня ПКТ каждые 1–2 дня после начала АБТ. Уровень ПКТ &lt; 0,5 нг / мл является безопасным для отмены АБТ у пациентов с сепсисом в отделении реанимации и интенсивной терапии (ОРИТ). Несмотря на то, что ПКТ не является совершенно специфичным для бактериальных инфекций, его концентрации повышаются и снижаются в соответствии с состоянием инфекционного процесса и его последующим разрешением, и положительно связаны с его тяжестью. К сожалению, мало доказательств в отношении эффективности и безопасности применения ПКТ у детей и новорожденных, а также в онкологии. Необходимы дальнейшие исследования в более однородных группах пациентов. Нет единого мнения о пороговых значениях ПКТ при различных ситуациях, а также нет международного стандарта по методам определения ПКТ. </p></abstract><kwd-group xml:lang="ru"><kwd>прокальцитонин</kwd><kwd>онкологические пациенты</kwd><kwd>сепсис</kwd><kwd>фебрильная нейтропения</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit..Care 2010;14: R15. DOI: 10.1186/cc8872</mixed-citation><mixed-citation xml:lang="en">Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit..Care 2010;14: R15. DOI: 10.1186/cc8872</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, openlabel trial. Lancet Infect Dis 2016;16:819e27. http://dx.doi.org/10.1016/</mixed-citation><mixed-citation xml:lang="en">de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, openlabel trial. Lancet Infect Dis 2016;16:819e27. http://dx.doi.org/10.1016/</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bonita Durnaś, Marzena Wątek, Tomasz- Wollny, Katarzyna Niemirowicz, Michał Marzec, Robert Bucki, Stanisław Góźdź. Utility of blood procalcitonin concentration in the management of cancer patients with infections. OncoTargets and Therapy 2016;9:469–475. http://dx.doi.org/10.2147/OTT.S95 600</mixed-citation><mixed-citation xml:lang="en">Bonita Durnaś, Marzena Wątek, Tomasz- Wollny, Katarzyna Niemirowicz, Michał Marzec, Robert Bucki, Stanisław Góźdź. Utility of blood procalcitonin concentration in the management of cancer patients with infections. OncoTargets and Therapy 2016;9:469–475. http://dx.doi.org/10.2147/OTT.S95 600</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49 (Suppl 1):S57 — S61. https://doi.org/10.2147/OTT.S95600</mixed-citation><mixed-citation xml:lang="en">Maruna P, Nedelnikova K, Gurlich R. Physiology and genetics of procalcitonin. Physiol Res. 2000;49 (Suppl 1):S57 — S61. https://doi.org/10.2147/OTT.S95600</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hochreiter M., Kohler T., Schweiger A. et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care, 2009;13 (3): R83 doi: 10.1186/cc7903.</mixed-citation><mixed-citation xml:lang="en">Hochreiter M., Kohler T., Schweiger A. et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Critical Care, 2009;13 (3): R83 doi: 10.1186/cc7903.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Brunkhorst F.M., Forycki Z.F., Wagner J . Identif ication of immunoactivation of infectious origin by procalcitonin in body fluids [Abstract]. In: First International Symposium in Iena of Intensive Care Medicine, 1996. Clin. Intensive Care Suppl. 7/1.</mixed-citation><mixed-citation xml:lang="en">Brunkhorst F.M., Forycki Z.F., Wagner J . Identif ication of immunoactivation of infectious origin by procalcitonin in body fluids [Abstract]. In: First International Symposium in Iena of Intensive Care Medicine, 1996. Clin. Intensive Care Suppl. 7/1.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Leon A., Lepouse C., Cousson J., et al. Procalcitonin in pleural effusion as a marker of septic response. [Abstract]. In: Fifth Vienna Shock Forum, 1995</mixed-citation><mixed-citation xml:lang="en">Leon A., Lepouse C., Cousson J., et al. Procalcitonin in pleural effusion as a marker of septic response. [Abstract]. In: Fifth Vienna Shock Forum, 1995</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 2017; published online Aug http://dx.doi.org/10.1016/S1473–3099(17)30396–1</mixed-citation><mixed-citation xml:lang="en">GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis 2017; published online Aug http://dx.doi.org/10.1016/S1473–3099(17)30396–1</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007–09. J Antimicrob Chemother 2014; 69: 234–40. doi: 10.1093/jac/dkt301</mixed-citation><mixed-citation xml:lang="en">Shapiro DJ, Hicks LA, Pavia AT, Hersh AL. Antibiotic prescribing for adults in ambulatory care in the USA, 2007–09. J Antimicrob Chemother 2014; 69: 234–40. doi: 10.1093/jac/dkt301</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med 2015; 373: 415–27. doi: 10.1056/NEJMoa1 500 245</mixed-citation><mixed-citation xml:lang="en">Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med 2015; 373: 415–27. doi: 10.1056/NEJMoa1 500 245</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B, Tamm M. Antibiotic treatment of exacerbations</mixed-citation><mixed-citation xml:lang="en">Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B, Tamm M. Antibiotic treatment of exacerbations</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">of COPD: a randomized, controlled trial comparing procalcitoninguidance with standard therapy. Chest. 2007 Jan;131 (1):9–19. DOI:10.1378/chest.06–1500</mixed-citation><mixed-citation xml:lang="en">of COPD: a randomized, controlled trial comparing procalcitoninguidance with standard therapy. Chest. 2007 Jan;131 (1):9–19. DOI:10.1378/chest.06–1500</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respirator y tract infections. Cochrane Database Syst Rev 2012;9: CD007 498. doi: 10.1002/14651858.CD007498.pub3</mixed-citation><mixed-citation xml:lang="en">Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respirator y tract infections. Cochrane Database Syst Rev 2012;9: CD007 498. doi: 10.1002/14651858.CD007498.pub3</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A, et al. Deescalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40:32–40. doi: 10.1007/s00134‑013‑3077‑7</mixed-citation><mixed-citation xml:lang="en">Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A, et al. Deescalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40:32–40. doi: 10.1007/s00134‑013‑3077‑7</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Schuetz P, Balk R, Briel M, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med 2015; 53:583–592. doi: 10.1515/cclm-2014–1015</mixed-citation><mixed-citation xml:lang="en">Schuetz P, Balk R, Briel M, et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med 2015; 53:583–592. doi: 10.1515/cclm-2014–1015</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Stojanovic I, Schneider JE, Wei L, et al. Economic evaluation of procalcitoninguided antibiotic therapy in acute respiratory infections: a Chinese hospital system perspective. Clin Chem Lab Med 2017; 55:561–570. doi: 10.1515/cclm-2016–0349</mixed-citation><mixed-citation xml:lang="en">Stojanovic I, Schneider JE, Wei L, et al. Economic evaluation of procalcitoninguided antibiotic therapy in acute respiratory infections: a Chinese hospital system perspective. Clin Chem Lab Med 2017; 55:561–570. doi: 10.1515/cclm-2016–0349</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017; 10: CD007 498. doi: 10.1002/14651858.CD007498.pub3</mixed-citation><mixed-citation xml:lang="en">Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2017; 10: CD007 498. doi: 10.1002/14651858.CD007498.pub3</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level metaanalysis. Lancet Infect Dis 2018; 18:95–107. doi:10.1016/S1473–3099 (17) 30 592–3.</mixed-citation><mixed-citation xml:lang="en">Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level metaanalysis. Lancet Infect Dis 2018; 18:95–107. doi:10.1016/S1473–3099 (17) 30 592–3.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Branche Angela, Neeser Olivia, Mueller Beat, Schuetz Philipp. Procalcitonin to guide antibiotic decision making. RESPIRATORY INFECTIONS: Edited by Michael S. Niederman: Curr Opin Infect Dis 2019; 32:130–135. DOI:10.1097/QCO.0000000000000522</mixed-citation><mixed-citation xml:lang="en">Branche Angela, Neeser Olivia, Mueller Beat, Schuetz Philipp. Procalcitonin to guide antibiotic decision making. RESPIRATORY INFECTIONS: Edited by Michael S. Niederman: Curr Opin Infect Dis 2019; 32:130–135. DOI:10.1097/QCO.0000000000000522</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Schuetz P, Kutz A, Grolimund E, et al. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol 2014; 175:464–472. doi: 10.1016/j.ijcard.2014.06.022.</mixed-citation><mixed-citation xml:lang="en">Schuetz P, Kutz A, Grolimund E, et al. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol 2014; 175:464–472. doi: 10.1016/j.ijcard.2014.06.022.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Schuetz P, Daniels LB, Kulkarni P, et al. Procalcitonin: a new biomarker for the cardiologist. Int J Cardiol 2016; 223:390–397. doi: 10.1016/j.ijcard.2016.08.204</mixed-citation><mixed-citation xml:lang="en">Schuetz P, Daniels LB, Kulkarni P, et al. Procalcitonin: a new biomarker for the cardiologist. Int J Cardiol 2016; 223:390–397. doi: 10.1016/j.ijcard.2016.08.204</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Llewelyn MJ, Fitzpatrick JM, Darwin E, et al. The antibiotic course has had its day. BMJ 2017; 358: j3418. doi: 10.1136/bmj.j3418</mixed-citation><mixed-citation xml:lang="en">Llewelyn MJ, Fitzpatrick JM, Darwin E, et al. The antibiotic course has had its day. BMJ 2017; 358: j3418. doi: 10.1136/bmj.j3418</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Schuetz P, Mueller B. Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes. Intensive Care Med 2014;40:141. doi: 10.1007/s00134‑013‑3139‑x.</mixed-citation><mixed-citation xml:lang="en">Schuetz P, Mueller B. Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes. Intensive Care Med 2014;40:141. doi: 10.1007/s00134‑013‑3139‑x.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Carr JA. Procalcitonin-guided antibiotic therapy for septic patients in the surgical intensive care unit. Journal of Intensive Care, 2015; 3: 36. doi: 10.1186/s40560‑015‑0100‑9.</mixed-citation><mixed-citation xml:lang="en">Carr JA. Procalcitonin-guided antibiotic therapy for septic patients in the surgical intensive care unit. Journal of Intensive Care, 2015; 3: 36. doi: 10.1186/s40560‑015‑0100‑9.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Schuetz P., Chiappa V., Briel et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine, 2011; 171 (15): 1322–1331. doi: 10.1001/archinternmed.2011.318</mixed-citation><mixed-citation xml:lang="en">Schuetz P., Chiappa V., Briel et al. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Archives of Internal Medicine, 2011; 171 (15): 1322–1331. doi: 10.1001/archinternmed.2011.318</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Nobre V, Harbar th S, Graf JD, et al. Use of procalcitonin to shor ten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177:498–505. DOI:10.1164/rccm.200708-1238OC</mixed-citation><mixed-citation xml:lang="en">Nobre V, Harbar th S, Graf JD, et al. Use of procalcitonin to shor ten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008; 177:498–505. DOI:10.1164/rccm.200708-1238OC</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Schuetz P, Birkhahn R, Sherwin R, et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin Monitoring SEpsis (MOSES) study. Crit Care Med 2017; 45:781–789. doi: 10.1097/CCM.0 000 000 000</mixed-citation><mixed-citation xml:lang="en">Schuetz P, Birkhahn R, Sherwin R, et al. Serial procalcitonin predicts mortality in severe sepsis patients: results from the multicenter procalcitonin Monitoring SEpsis (MOSES) study. Crit Care Med 2017; 45:781–789. doi: 10.1097/CCM.0 000 000 000</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">321</mixed-citation><mixed-citation xml:lang="en">321</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">van der Does Y, Limper M, Jie KE, et al. Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a multicentre noninferiority randomized clinical trial (HiTEMP study). Clin Microbiol Infect 2018; 24:1282–1289. doi: 10.1016/j.cmi.2018.05.011.</mixed-citation><mixed-citation xml:lang="en">van der Does Y, Limper M, Jie KE, et al. Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a multicentre noninferiority randomized clinical trial (HiTEMP study). Clin Microbiol Infect 2018; 24:1282–1289. doi: 10.1016/j.cmi.2018.05.011.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Schuetz P, Falsey AR. Procalcitonin in patients with fever: one approach does not fit all. Clin Microbiol Infect 2018; 24:1229–1230. doi: 10.1016/j.cmi.2018.07.022</mixed-citation><mixed-citation xml:lang="en">Schuetz P, Falsey AR. Procalcitonin in patients with fever: one approach does not fit all. Clin Microbiol Infect 2018; 24:1229–1230. doi: 10.1016/j.cmi.2018.07.022</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Huang DT, Yealy DM, Filbin MR, Brown AM, Chang CH, Doi Y, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med 2018; 379:236–249. doi: 10.1056/NEJMoa1802670</mixed-citation><mixed-citation xml:lang="en">Huang DT, Yealy DM, Filbin MR, Brown AM, Chang CH, Doi Y, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med 2018; 379:236–249. doi: 10.1056/NEJMoa1802670</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Reynolds SC, Shorr AF, Muscedere J , Jiang X, Heyland DK. Longitudinal changes in procalcitonin in a heterogeneous group of critically ill patients. Crit Care Med 2012; 40: 2781–87. DOI:10.1097/CCM.0b013e31 825b89cc</mixed-citation><mixed-citation xml:lang="en">Reynolds SC, Shorr AF, Muscedere J , Jiang X, Heyland DK. Longitudinal changes in procalcitonin in a heterogeneous group of critically ill patients. Crit Care Med 2012; 40: 2781–87. DOI:10.1097/CCM.0b013e31 825b89cc</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014; 42: 1749–55. doi: 10.1097/CCM.0 000 000 000 000 330</mixed-citation><mixed-citation xml:lang="en">Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014; 42: 1749–55. doi: 10.1097/CCM.0 000 000 000 000 330</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38: 1045–53. doi: 10.1097/CCM.0b013e3181cc4824</mixed-citation><mixed-citation xml:lang="en">Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38: 1045–53. doi: 10.1097/CCM.0b013e3181cc4824</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Fontela PS, Quach C, Karim ME, et al. Determinants of antibiotic tailoring in pediatric intensive care: a national survey. Pediatr Crit Care Med 2017; 18: e395 — e405. doi: 10.1097/PCC.0 000 000 000 001 238</mixed-citation><mixed-citation xml:lang="en">Fontela PS, Quach C, Karim ME, et al. Determinants of antibiotic tailoring in pediatric intensive care: a national survey. Pediatr Crit Care Med 2017; 18: e395 — e405. doi: 10.1097/PCC.0 000 000 000 001 238</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Cremieux AC, Muller-Serieys C, Panhard X, et al. Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin-clavulanic acid treatments. Ant imicrob Agents Chemother 2003; 47: 2030–35. doi:</mixed-citation><mixed-citation xml:lang="en">Cremieux AC, Muller-Serieys C, Panhard X, et al. Emergence of resistance in normal human aerobic commensal flora during telithromycin and amoxicillin-clavulanic acid treatments. Ant imicrob Agents Chemother 2003; 47: 2030–35. doi:</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">1128/AAC.47.6.2030–2035.2003</mixed-citation><mixed-citation xml:lang="en">1128/AAC.47.6.2030–2035.2003</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">van Bijnen EME, Paget J, de Lange-de Klerk ESM, et al. Antibiotic exposure and other risk factors for antimicrobial resistance in nasal commensal Staphylococcus aureus: an ecological study in 8 European countries. PLoS One 2015; 10: e0 135 094. doi.org/10.1371/journal.pone.0 135 094</mixed-citation><mixed-citation xml:lang="en">van Bijnen EME, Paget J, de Lange-de Klerk ESM, et al. Antibiotic exposure and other risk factors for antimicrobial resistance in nasal commensal Staphylococcus aureus: an ecological study in 8 European countries. PLoS One 2015; 10: e0 135 094. doi.org/10.1371/journal.pone.0 135 094</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Dubos F., Korczowski B., Aygun D.A. et al. Distinguishing between bacterial and aseptic meningitis in children: European comparison of two clinical decision rules. Arch. Dis. Child., 2010; 95: 963–967. DOI: 10.1136/adc.2010.186056</mixed-citation><mixed-citation xml:lang="en">Dubos F., Korczowski B., Aygun D.A. et al. Distinguishing between bacterial and aseptic meningitis in children: European comparison of two clinical decision rules. Arch. Dis. Child., 2010; 95: 963–967. DOI: 10.1136/adc.2010.186056</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Leroy S., Gervaix A. Procalcitonin: a key marker in children with urinary tract infection. Adv. Urol., 2011;397 618 21 274 426. doi: 10.1155/2011/397618</mixed-citation><mixed-citation xml:lang="en">Leroy S., Gervaix A. Procalcitonin: a key marker in children with urinary tract infection. Adv. Urol., 2011;397 618 21 274 426. doi: 10.1155/2011/397618</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Galetto-Lacour A., Alcoba G., Posfay-Barbe K.M. et al. Elevated inflammatory markers combined with positive pneumococcal urinary antigen are a good predictor of pneumococcal communityacquired pneumonia in children. Pediatr. Infect. Dis J., 2013; 32 (11): 1175–1179. doi:10.1097/INF.0b013e31 829ba62a</mixed-citation><mixed-citation xml:lang="en">Galetto-Lacour A., Alcoba G., Posfay-Barbe K.M. et al. Elevated inflammatory markers combined with positive pneumococcal urinary antigen are a good predictor of pneumococcal communityacquired pneumonia in children. Pediatr. Infect. Dis J., 2013; 32 (11): 1175–1179. doi:10.1097/INF.0b013e31 829ba62a</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Westwood ME, Ramaekers BLT, Whiting P, Tomini F, Joore MA, Armstrong N, et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess 2015;19 (96). DOI: 10.3310/hta19960</mixed-citation><mixed-citation xml:lang="en">Westwood ME, Ramaekers BLT, Whiting P, Tomini F, Joore MA, Armstrong N, et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess 2015;19 (96). DOI: 10.3310/hta19960</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Mewes JC, Pulia MS, Mansour MK, Broyles MR, Nguyen HB, Steuten LM (2019) The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patient s with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. PLoS ONE 14 (4): e0 214 222. https://doi.org /10.1371/journal.pone.0214222</mixed-citation><mixed-citation xml:lang="en">Mewes JC, Pulia MS, Mansour MK, Broyles MR, Nguyen HB, Steuten LM (2019) The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patient s with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis. PLoS ONE 14 (4): e0 214 222. https://doi.org /10.1371/journal.pone.0214222</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Iankova I, Thompson-Leduc P, Kirson NY, Rice B, Hey J, Krause A, et al. Efficacy and safety of procalcitonin guidance in patients with suspected or confirmed sepsis: a systematic review and metaanalysis. Crit Care Med. 2018;46:691–698. doi: 10.1097/CCM.0 000 000 000 002 928.</mixed-citation><mixed-citation xml:lang="en">Iankova I, Thompson-Leduc P, Kirson NY, Rice B, Hey J, Krause A, et al. Efficacy and safety of procalcitonin guidance in patients with suspected or confirmed sepsis: a systematic review and metaanalysis. Crit Care Med. 2018;46:691–698. doi: 10.1097/CCM.0 000 000 000 002 928.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Patout M, Salaun M, B runel V, Bota S , Caul ie z B , Thiberville L. Diag¬nostic and prognostic value of serum procalcitonin concentrations in primary lung cancers. Clin Biochem. 2014;47 (18):263–267. doi:10.1016/j.clinbiochem.2014.09.002</mixed-citation><mixed-citation xml:lang="en">Patout M, Salaun M, B runel V, Bota S , Caul ie z B , Thiberville L. Diag¬nostic and prognostic value of serum procalcitonin concentrations in primary lung cancers. Clin Biochem. 2014;47 (18):263–267. doi:10.1016/j.clinbiochem.2014.09.002</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis. 2006;43 (4):468–473. DOI:10.1086/505 394</mixed-citation><mixed-citation xml:lang="en">Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C. Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis. 2006;43 (4):468–473. DOI:10.1086/505 394</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Schuetz P.B., Mueller, A. Trampuz. Contamination from Bloodstream Infection due to Coagulase-Negative Staphylococci. Infection, 2007, 35 (5): 352–355. DOI 10.1007/s15010‑007‑7065‑0</mixed-citation><mixed-citation xml:lang="en">Schuetz P.B., Mueller, A. Trampuz. Contamination from Bloodstream Infection due to Coagulase-Negative Staphylococci. Infection, 2007, 35 (5): 352–355. DOI 10.1007/s15010‑007‑7065‑0</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: A prospective cohort trial. Chest, 2010, 138: 121–129. DOI:10.1378/chest.09–2920</mixed-citation><mixed-citation xml:lang="en">Müller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: A prospective cohort trial. Chest, 2010, 138: 121–129. DOI:10.1378/chest.09–2920</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Hanine El Haddad, Anne-Marie Chaftari, Ray Hachem, Patrick Chaftari, and Issam I. Raad. Biomarkers of Sepsis and Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin With Emphasis in Patients With Cancer. Clinical Infectious Diseases® 2018;67 (6):971–7. DOI:10.1093/cid/ciy331</mixed-citation><mixed-citation xml:lang="en">Hanine El Haddad, Anne-Marie Chaftari, Ray Hachem, Patrick Chaftari, and Issam I. Raad. Biomarkers of Sepsis and Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin With Emphasis in Patients With Cancer. Clinical Infectious Diseases® 2018;67 (6):971–7. DOI:10.1093/cid/ciy331</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Matzaraki V, Alexandraki KI, Venetsanou K, et al. Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem 2007;40:336–42. DOI:10.1016/j.clinbiochem.2006.10.027</mixed-citation><mixed-citation xml:lang="en">Matzaraki V, Alexandraki KI, Venetsanou K, et al. Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem 2007;40:336–42. DOI:10.1016/j.clinbiochem.2006.10.027</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Chaftari AM, Hachem R, Reitzel R, et al. Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection. PLOS One 2015; 10: e0 130 999. doi: 10.1371/journal.pone.0130999</mixed-citation><mixed-citation xml:lang="en">Chaftari AM, Hachem R, Reitzel R, et al. Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection. PLOS One 2015; 10: e0 130 999. doi: 10.1371/journal.pone.0130999</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Ilhan N, Ilhan N, Ilhan Y, Akbulut H, Kucuksu M. C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol 2004; 10:1115–20. DOI:10.3748/wjg.v10.i8.1115</mixed-citation><mixed-citation xml:lang="en">Ilhan N, Ilhan N, Ilhan Y, Akbulut H, Kucuksu M. C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol 2004; 10:1115–20. DOI:10.3748/wjg.v10.i8.1115</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Ittner L, Born W, Rau B, Steinbach G, Fischer JA. Circulating procalcitonin and cleavage products in septicaemia compared with medullary thyroid carcinoma. Eur J Endocrinol 2002; 147:727–31. DOI:10.1530/eje.0.1 470 727</mixed-citation><mixed-citation xml:lang="en">Ittner L, Born W, Rau B, Steinbach G, Fischer JA. Circulating procalcitonin and cleavage products in septicaemia compared with medullary thyroid carcinoma. Eur J Endocrinol 2002; 147:727–31. DOI:10.1530/eje.0.1 470 727</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Avrillon V, Locatelli-Sanchez M, Folliet L, et al. Lung cancer may increase serum procalcitonin level. Infect Disord Drug Targets 2015; 15:57–63.</mixed-citation><mixed-citation xml:lang="en">Avrillon V, Locatelli-Sanchez M, Folliet L, et al. Lung cancer may increase serum procalcitonin level. Infect Disord Drug Targets 2015; 15:57–63.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Shen H, Zheng S, Chen R, et al. Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization: a retrospective analysis of 509 cases. Medicine (Baltimore) 2017; 96: e7438. doi:10.1097/MD.0 000 000 000 007 438</mixed-citation><mixed-citation xml:lang="en">Shen H, Zheng S, Chen R, et al. Prognostic significance of serum procalcitonin in patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization: a retrospective analysis of 509 cases. Medicine (Baltimore) 2017; 96: e7438. doi:10.1097/MD.0 000 000 000 007 438</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Chen L, Zhang Y, Lin Y, et al. The role of elevated serum procalcitonin in neuroendocrine neoplasms of digestive system. Clin Biochem 2017; 50:982–7. doi: 10.1016/j.clinbiochem.2017.06.010</mixed-citation><mixed-citation xml:lang="en">Chen L, Zhang Y, Lin Y, et al. The role of elevated serum procalcitonin in neuroendocrine neoplasms of digestive system. Clin Biochem 2017; 50:982–7. doi: 10.1016/j.clinbiochem.2017.06.010</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Yaegashi H, Izumi K, Kitagawa Y, et al. Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: the role of procalcitonin. Int J Urol 2014; 21:104–6. doi: 10.1111/iju.12 178.</mixed-citation><mixed-citation xml:lang="en">Yaegashi H, Izumi K, Kitagawa Y, et al. Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: the role of procalcitonin. Int J Urol 2014; 21:104–6. doi: 10.1111/iju.12 178.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Shomali W, Hachem R, Chaftari AM, et al. Can procalcitonin distinguish infectious fever from tumor-related fever in nonneutropenic cancer patient s? Cancer 2012; 118:5823–9. doi:10.1002/cncr.27 602.</mixed-citation><mixed-citation xml:lang="en">Shomali W, Hachem R, Chaftari AM, et al. Can procalcitonin distinguish infectious fever from tumor-related fever in nonneutropenic cancer patient s? Cancer 2012; 118:5823–9. doi:10.1002/cncr.27 602.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Gac AC, Parienti JJ, Chantepie S, et al. Dynamics of procalcitonin and bacteremia in neutropenic adults with acute myeloid leukemia. Leuk Res. 2011;35 (10):1294–1296. doi: 10.1016/j.leukres.2011</mixed-citation><mixed-citation xml:lang="en">Gac AC, Parienti JJ, Chantepie S, et al. Dynamics of procalcitonin and bacteremia in neutropenic adults with acute myeloid leukemia. Leuk Res. 2011;35 (10):1294–1296. doi: 10.1016/j.leukres.2011</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Carnino L, Betteto S, Loiacono M, et al. Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. J Cancer Res Clin Oncol. 2010;136 (4):611–615. doi: 10.1007/s00432‑009‑0699‑9</mixed-citation><mixed-citation xml:lang="en">Carnino L, Betteto S, Loiacono M, et al. Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. J Cancer Res Clin Oncol. 2010;136 (4):611–615. doi: 10.1007/s00432‑009‑0699‑9</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Al Shuaibi M, Bahu RR, Chaftari AM, et al. Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies. Clin Infect Dis 2013; 56:943–50. doi: 10.1093/cid/cis1029</mixed-citation><mixed-citation xml:lang="en">Al Shuaibi M, Bahu RR, Chaftari AM, et al. Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies. Clin Infect Dis 2013; 56:943–50. doi: 10.1093/cid/cis1029</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Lucena CM, Rovira M, Gabarrus A, et al. The clinical value of biomarkers in respiratory complications in hematopoietic SCT. Bone Marrow Transplant 2017;52:415–22. doi:10.1038/bmt.2016.280</mixed-citation><mixed-citation xml:lang="en">Lucena CM, Rovira M, Gabarrus A, et al. The clinical value of biomarkers in respiratory complications in hematopoietic SCT. Bone Marrow Transplant 2017;52:415–22. doi:10.1038/bmt.2016.280</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Debiane L, Hachem RY, Al Wohoush I, et al. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*. Crit Care Med 2014; 42:2500–7. doi: 10.1097/CCM.0 000 000 000 000 526</mixed-citation><mixed-citation xml:lang="en">Debiane L, Hachem RY, Al Wohoush I, et al. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer*. Crit Care Med 2014; 42:2500–7. doi: 10.1097/CCM.0 000 000 000 000 526</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Rast AC, Kutz A, Felder S, et al. Procalcitonin improves the Glasgow Prognostic Score for outcome prediction in emergency patients with cancer: a cohort study. Dis Markers 2015; 2015:795 801. doi: 10.1155/2015/795 801</mixed-citation><mixed-citation xml:lang="en">Rast AC, Kutz A, Felder S, et al. Procalcitonin improves the Glasgow Prognostic Score for outcome prediction in emergency patients with cancer: a cohort study. Dis Markers 2015; 2015:795 801. doi: 10.1155/2015/795 801</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Ahn S, Lee YS, Lim KS, Lee JL. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer 2013; 21:2303–8. doi: 10.1007/s00 520‑013‑1787‑6</mixed-citation><mixed-citation xml:lang="en">Ahn S, Lee YS, Lim KS, Lee JL. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer 2013; 21:2303–8. doi: 10.1007/s00 520‑013‑1787‑6</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Lima SS, Nobre V, de Castro Romanelli RM, et al. Procalcitoninguided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Ann Hematol 2016; 95:1169–76. doi: 10.1007/s00277‑016‑2639‑5</mixed-citation><mixed-citation xml:lang="en">Lima SS, Nobre V, de Castro Romanelli RM, et al. Procalcitoninguided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Ann Hematol 2016; 95:1169–76. doi: 10.1007/s00277‑016‑2639‑5</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Haddad HE, Chaftari AM, Hachem R, et al. Procalcitonin guiding antimicrobial therapy duration in febrile cancer patients with documented infection or neutropenia. Sci Rep 2018; 8:1099. doi: 10.1038/s41 598‑018‑19 616‑3</mixed-citation><mixed-citation xml:lang="en">Haddad HE, Chaftari AM, Hachem R, et al. Procalcitonin guiding antimicrobial therapy duration in febrile cancer patients with documented infection or neutropenia. Sci Rep 2018; 8:1099. doi: 10.1038/s41 598‑018‑19 616‑3</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, BeaucheminM, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol 2017; 35:2082–2094. https://doi.org /10.1200/JCO.2016.71.7017</mixed-citation><mixed-citation xml:lang="en">Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, BeaucheminM, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol 2017; 35:2082–2094. https://doi.org /10.1200/JCO.2016.71.7017</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Miedema KGE, De Bont ESJM, Elferink RFMO et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer. 2011; 19:1593–1600. https://doi.org/10.1007/s00 520‑010‑0987‑6</mixed-citation><mixed-citation xml:lang="en">Miedema KGE, De Bont ESJM, Elferink RFMO et al. The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer. 2011; 19:1593–1600. https://doi.org/10.1007/s00 520‑010‑0987‑6</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Hodgson-Viden H, Grundy PE, Robinson JL et al . Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatr. 2005; 5:10. https://doi.org/10.1186/1471‑2431‑5‑10</mixed-citation><mixed-citation xml:lang="en">Hodgson-Viden H, Grundy PE, Robinson JL et al . Early discontinuation of intravenous antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC Pediatr. 2005; 5:10. https://doi.org/10.1186/1471‑2431‑5‑10</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Hilde T. van der Galiën &amp; Erik A.H. Loeffen &amp; Karin G.E. Miedema1&amp; Wim J.E. Tissing. Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia. Supportive Care in Cancer. 2018; 26:3819–3826. https://doi.org/10.1007/s00 520‑018‑4249‑3</mixed-citation><mixed-citation xml:lang="en">Hilde T. van der Galiën &amp; Erik A.H. Loeffen &amp; Karin G.E. Miedema1&amp; Wim J.E. Tissing. Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia. Supportive Care in Cancer. 2018; 26:3819–3826. https://doi.org/10.1007/s00 520‑018‑4249‑3</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
